Literature DB >> 32016715

Comment On: "Stratifying Therapeutic Enoxaparin Dose in Morbidly Obese Patients by BMI Class: A Retrospective Cohort Study".

Nameer van Oosterom1,2, Karl Winckel3,4, Michael Barras3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32016715     DOI： 10.1007/s40261-020-00889-4

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN： 1173-2563            Impact factor:   2.859


× No keyword cloud information.
  5 in total

Review 1.  Antithrombotic therapy in children.

Authors:  P Monagle; A D Michelson; E Bovill; M Andrew
Journal:  Chest       Date:  2001-01       Impact factor: 9.410

2.  Evaluation of weight based enoxaparin dosing on anti-Xa concentrations in patients with obesity.

Authors:  Nameer van Oosterom; Karl Winckel; Michael Barras
Journal:  J Thromb Thrombolysis       Date:  2019-10       Impact factor: 2.300

3.  Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators.

Authors: 
Journal:  J Am Coll Cardiol       Date:  1997-06       Impact factor: 24.094

4.  Individualized dosing of enoxaparin for subjects with renal impairment is superior to conventional dosing at achieving therapeutic concentrations.

Authors:  Michael A Barras; Stephen B Duffull; John J Atherton; Bruce Green
Journal:  Ther Drug Monit       Date:  2010-08       Impact factor: 3.681

5.  Stratifying Therapeutic Enoxaparin Dose in Morbidly Obese Patients by BMI Class: A Retrospective Cohort Study.

Authors:  Young R Lee; Peter J Palmere; Caitlin E Burton; Taylor M Benavides
Journal:  Clin Drug Investig       Date:  2020-01       Impact factor: 2.859
  5 in total
  1 in total

1.  Response to Comment on: "Stratifying Therapeutic Enoxaparin Dose in Morbidly Obese Patients by BMI Class: A Retrospective Cohort Study".

Authors:  Young R Lee
Journal:  Clin Drug Investig       Date:  2020-03       Impact factor: 2.859
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.